Clinical efficacy and safety of rituximab extended interval dosing in patients with MS

Authors
Category Primary study
ConferenceThe 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Year 2024
This article has no abstract
Epistemonikos ID: 565f281632c862ac0d868090ff35c464909d3640
First added on: Apr 04, 2026